Роль воспалительной теории в патогенезе фибрилляции предсердий

На основании данных, имеющихся в литературе, очевидно, что воспаление играет значимую роль в инициации, поддержании и прогрессировании ФП. Однако, немаловажными представляются данные и о том, что сама по себе фибрилляция является фактором, провоцирующим развитие воспаления в миокарде предсердия, что, соответственно, приводит к дальнейшему прогрессированию заболевания по принципу “ФП порождает ФП”. К настоящему моменту остается не до конца изученным вопрос о первичности возникновения и взаимосвязи звеньев данного процесса: воспаление порождает фибрилляцию или фибрилляция порождает воспаление, которое в дальнейшем приводит к прогрессированию заболевания?

Авторы статьи, проанализировав данные мировой литературы, попытались описать основные концепции воспалительной теории ФП и практические аспекты ее применения.

1. Ha'i'ssaguerre M, Ja'i's P, Shah DC, et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med. 1998;339(10):659-66. doi:10.1056/NEJM199809033391003.

2. Hakalahti A, Biancari F, Nielsen JC, et al. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015;17(3):370-8. doi:101093/europace/euu376.

3. Heeger C-H, Kuck K-H, Ouyang F. Pulmonal vene nisolation bei Vorhofflimmern. Herz. 2017;42(4):343-51. doi:10.1007/s00059-017-4565-2.

4. Frost L, Johnsen SP, Pedersen L, et al. Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology. 2002;13(2):211-5. doi:10.1097/00001648-200203000-00017.

5. Tsai F-C, Chang G-J, Hsu Y-J, et al. Proinflammatory gene expression in patients undergoing mitral valve surgery and maze ablation for atrial fibrillation. J Thorac Cardiovasc Surg. 2016;151(6):1673-82.e5. doi:10.1016/j.jtcvs.2015.12.003.

6. Shiroshitatakeshita A, Brundel B, Lavoie J, et al. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006;69(4):865-75. doi:10.1016/j.cardiores.2005.11.028.

7. Frustaci A, Caldarulo M, Buffon A, et al. Cardiac biopsy in patients with “primary” atrial fibrillation; Histologic evidence of occult myocardial diseases. Chest. 1991;100(2):303-6. doi.org/10.1378/chest.100.2.303.

8. Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol. 2007;120(2):193-7 doi:10.1016/j.ijcard.2006.09.015.

9. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. European Heart Journal.2004;25:1100-107. doi:10.1016/j.ehj.2004.04.035.

10. Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid administration associated with a reduced incidence of postoperative atrial fi brillation in adult cardiac surgery. Interactive CardioVascular and Thoracic Surgery. 2014;18:225-9. doi:101093/icvts/ivt486.

11. Musa H, Kaur K, O'connell R, et al. Inhibition of Platelet-Derived Growth Factor-AB Signaling Prevents Electromechanical Remodeling of Adult Atrial Myocytes that Contact Myofibroblasts. Heart Rhythm. 2013;10(7):1044-51. doi:10.1016/j.hrthm.2013.03.014.

12. Tselentakis EV, Woodford E, Chandy J, et al. Inflammation Effects on the Electrical Properties of Atrial Tissue and Inducibility of Postoperative Atrial Fibrillation. Journal of Surgical Research. 2006;135:68-75. doi:10.1016/j.jss.2006.03.024.

13. Ryu K, Li L, Khrestian CM, et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am J Physiol Hear Circ Physiol. 2007; 293:1231-41. doi:10.1152/ajpheart.00607.2006.

14. Sawaya SE, Rajawat YS, Rami TG, et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Hear Circ Physiol. 2007;292:1561-7. doi:101152/ajpheart.00285.2006.

15. Liew R, Khairunnisa K, Gu Y, et al. Role of tumor necrosis factor-а in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J. 2013;77(5):1171-9. doi:10.1253/circj.CJ-12-1155.

16. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by antitumor necrosis factor alpha therapy. Proc Natl Acad Sci USA. 2000;97(23): 12746-51. doi:10.1073/pnas.97.23.12746.

17. Liao C-H, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120. doi:10.1172/JCI39942.

18. Burstein B, Libby E, Calderone A, et al. Differential Behaviors of Atrial Versus Ventricular Fibroblasts A Potential Role for Platelet-Derived Growth Factor in Atrial-Ventricular Remodeling Differences. Circulation. 2008; 117:1630-41. doi: 10.1161/CIRCULATIONAHA.107.748053.

19. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace. 2010;12(12):1713-8. doi:10.1093/europace/euq321.

20. Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95(6):764-7. doi:10.1016/j.amjcard.2004.11.032.

21. Roldan V, Marin F, Diaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500-7. doi:10.1111/j.1538-7836.2012.04812.x.

22. Lip GYH, Patel J V., Hughes E, et al. High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation. Stroke. 2007;38(4):1229-37. doi:10.1161/01.STR.0000260090.90508.3e.

23. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thrombosis Research. 2003;111:137-42. doi:10.1016/S0049-3848(03)00405-5.

24. Lu T-F, Lin T-M, Tsao Y-J, et al. Plasma Asymmetric Dimethylarginine and Adverse Events in Patients with Atrial Fibrillation Referred for Coronary Angiogram. PLoS One. 2013;8(8):71675. doi:10.1371/journal.pone.0071675.

25. Roldan V, Marin F, Muina B, et al. Atrial Fibrillation Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. JAC. 2011;57:2496-504. doi: 10.1016/j.jacc.2010.12.033.

26. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand Factor in the Endocardium as a Local Predisposing Factor for Thrombogenesis in Overloaded Human Atrial Appendage. JACC. 2001;5:1436-42. doi:10.1016/S0735-1097(01)01125-1.

27. Conway DSG, Buggins P, Hughes E, et al. Relation of Interleukin-6, C-Reactive Protein, and the Prothrombotic State to Transesophageal Echocardiographic Findings in Atrial Fibrillation. Am J Cardiol. 2004;93. doi:10.1016/j.amjcard.2004.02.032.